Artigos de revistas sobre o tema "Docetaxel resistance"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Docetaxel resistance".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Kroon, Jan, Martin Puhr, Jeroen T. Buijs, Geertje van der Horst, Daniëlle M. Hemmer, Koen A. Marijt, Ming S. Hwang et al. "Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer". Endocrine-Related Cancer 23, n.º 1 (19 de outubro de 2015): 35–45. http://dx.doi.org/10.1530/erc-15-0343.
Texto completo da fonteILHAN, Suleyman. "Effect of interleukin-8 on docetaxel resistance in prostate cancer cells: insights into the role of multidrug resistance 1 protein modulation". Cancer Insight 2, n.º 1 (14 de junho de 2023): 53–67. http://dx.doi.org/10.58567/ci02010004.
Texto completo da fonteShen, Weiwei, Hailin Pang, Jiayu Liu, Jing Zhou, Feng Zhang, Lele Liu, Ningqiang Ma, Ning Zhang, Helong Zhang e Lili Liu. "EpithelialMesenchymal Transition Contributes to Docetaxel Resistance in Human Non-Small Cell Lung Cancer". Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 22, n.º 1 (23 de outubro de 2014): 47–55. http://dx.doi.org/10.3727/096504014x14098532393473.
Texto completo da fonteFrancini, Edoardo, Fang-Shu Ou, Justin Rhoades, Eric G. Wolfe, Edward P. O’Connor, Gavin Ha, Gregory Gydush et al. "Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer". Cancers 13, n.º 16 (12 de agosto de 2021): 4055. http://dx.doi.org/10.3390/cancers13164055.
Texto completo da fonteZu, Shulu, Weiming Ma, Pan Xiao, Yazhou Cui, Tianjia Ma, Chunwen Zhou e Huaiqiang Zhang. "Evaluation of Docetaxel-Sensitive and Docetaxel-Resistant Proteomes in PC-3 Cells". Urologia Internationalis 95, n.º 1 (2015): 114–19. http://dx.doi.org/10.1159/000351263.
Texto completo da fonteLima, Thiago S., Diego Iglesias-Gato, Luciano D. O. Souza, Jan Stenvang, Diego S. Lima, Martin A. Røder, Klaus Brasso e José M. A. Moreira. "Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance". Cancers 13, n.º 6 (14 de março de 2021): 1290. http://dx.doi.org/10.3390/cancers13061290.
Texto completo da fonteBukhari, Nedal, Kylea R. Potvin, D. Scott Ernst, Lori Sax e Eric Winquist. "Early docetaxel-resistance in metastatic hormone-sensitive prostate cancer." Journal of Clinical Oncology 35, n.º 6_suppl (20 de fevereiro de 2017): 260. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.260.
Texto completo da fonteGruber, Martina, Lavinia Ferrone, Martin Puhr, Frédéric R. Santer, Tobias Furlan, Iris E. Eder, Natalie Sampson, Georg Schäfer, Florian Handle e Zoran Culig. "p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer". Endocrine-Related Cancer 27, n.º 3 (março de 2020): 187–98. http://dx.doi.org/10.1530/erc-19-0488.
Texto completo da fonteZhao, Song, Ilsa Coleman, Roger Coleman e Peter Nelson. "Association of PARP inhibitors and docetaxel resistance through suppressing a tumor microenvironment-associated secretory program." Journal of Clinical Oncology 31, n.º 15_suppl (20 de maio de 2013): e22212-e22212. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e22212.
Texto completo da fonteWróbel, Tomasz, Marcin Luty, Jessica Catapano, Elżbieta Karnas, Małgorzata Szczygieł, Katarzyna Piwowarczyk, Damian Ryszawy et al. "CD44+ cells determine fenofibrate-induced microevolution of drug-resistance in prostate cancer cell populations". Stem Cells 38, n.º 12 (2 de outubro de 2020): 1544–56. http://dx.doi.org/10.1002/stem.3281.
Texto completo da fonteLiu, Rong-Zong, Mansi Garg, Xiao-Hong Yang e Roseline Godbout. "Docetaxel-Induced Cell Death Is Regulated by a Fatty Acid-Binding Protein 12-Slug-Survivin Pathway in Prostate Cancer Cells". International Journal of Molecular Sciences 25, n.º 17 (6 de setembro de 2024): 9669. http://dx.doi.org/10.3390/ijms25179669.
Texto completo da fonteShimizu, Yasuomi, Satoshi Tamada, Minoru Kato, Yukiyoshi Hirayama, Yuji Takeyama, Taro Iguchi, Marianne Sadar e Tatsuya Nakatani. "Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy". Journal of Clinical Medicine 7, n.º 11 (16 de novembro de 2018): 444. http://dx.doi.org/10.3390/jcm7110444.
Texto completo da fonteLiu, Xiao Dong, Yi Ju Hou, Lin Zhang e Hui Ling Cao. "Compound Injection of Shenqi as a Reversal Drug on Docetaxel Resistant Human Lung Adenocarcinoma Cell A549/DTX". Advanced Materials Research 926-930 (maio de 2014): 1054–57. http://dx.doi.org/10.4028/www.scientific.net/amr.926-930.1054.
Texto completo da fonteSong, Liankun, Vyvyan Nguyen, Jun Xie, Matthew Tippin, Le TP Truong, Christopher A. Blair, Beverly Wang, Edward Uchio e Xiaolin Zi. "Abstract 1687: ATPase copper transporting beta (ATP7B) contributes to acquired docetaxel resistance in human prostate cancer". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 1687. http://dx.doi.org/10.1158/1538-7445.am2023-1687.
Texto completo da fonteYin, Beibei, Ping Lu, Jing Liang, Wei Zhang, Meng Xin, Ke Pei e Yan Li. "The ABCB1 3435C > T polymorphism influences docetaxel transportation in ovarian cancer". Journal of International Medical Research 47, n.º 10 (6 de setembro de 2019): 5256–69. http://dx.doi.org/10.1177/0300060519870354.
Texto completo da fonteRiedel, R. F., A. Porrello, E. Chenette, A. Potti, J. R. Nevins e P. G. Febbo. "A genomic approach to identify mechanisms associated with chemotherapy resistance". Journal of Clinical Oncology 25, n.º 18_suppl (20 de junho de 2007): 2534. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.2534.
Texto completo da fonteAndo, Masashi, Toru Watanabe, Kazuhiro Nagata, Masaru Narabayashi, Isamu Adachi e Noriyuki Katsumata. "Efficacy of Docetaxel 60 mg/m2 in Patients With Metastatic Breast Cancer According to the Status of Anthracycline Resistance". Journal of Clinical Oncology 19, n.º 2 (15 de janeiro de 2001): 336–42. http://dx.doi.org/10.1200/jco.2001.19.2.336.
Texto completo da fonteŞumnulu, Deniz, e Zeynep Doğanlar. "Aba enhances the apoptotic effect of docetaxel in the multidrug-resistant DU145 prostate cancer cell line". Archives of Biological Sciences, n.º 00 (2024): 31. http://dx.doi.org/10.2298/abs240812031s.
Texto completo da fonteShimizu, Yasuomi, Minoru Kato, Yuji Takeyama, Kosuke Hamada, Taro Iguchi, Satoshi Tamada e Tatsuya Nakatani. "The effect of androgen receptor splice variant 7 on the growth of castration-resistant prostate cancer and the efficacy of taxane chemotherapy." Journal of Clinical Oncology 37, n.º 7_suppl (1 de março de 2019): 302. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.302.
Texto completo da fonteSchaaf, Zachary A., Shu Ning, Amy R. Leslie, Masuda Sharifi, Xianrui Han, Cameron Armstrong, Wei Lou, Alan P. Lombard, Chengfei Liu e Allen C. Gao. "Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer". Cancers 15, n.º 21 (3 de novembro de 2023): 5273. http://dx.doi.org/10.3390/cancers15215273.
Texto completo da fonteByun, Woong Sub, Eun Seo Bae, Jinsheng Cui, Hyen Joo Park, Dong-Chan Oh e Sang Kook Lee. "Antitumor Activity of Pulvomycin via Targeting Activated-STAT3 Signaling in Docetaxel-Resistant Triple-Negative Breast Cancer Cells". Biomedicines 9, n.º 4 (17 de abril de 2021): 436. http://dx.doi.org/10.3390/biomedicines9040436.
Texto completo da fonteSanchez, Bertha E., Nilesh Gupta, Meredith Mahan, Evelyn R. Barrack, Prem-veer Reddy e Clara Hwang. "βIII-tubulin expression as a predictor of docetaxel resistance in metastatic castrate-resistant prostate cancer." Journal of Clinical Oncology 30, n.º 15_suppl (20 de maio de 2012): e15174-e15174. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e15174.
Texto completo da fonte&NA;. "Aberdeen researchers develop probe for docetaxel resistance". Oncology Times UK 4, n.º 11 (novembro de 2007): 7. http://dx.doi.org/10.1097/01434893-200711000-00007.
Texto completo da fonteFenner, Annette. "Antiandrogens reverse docetaxel resistance via ABCB1 inhibition". Nature Reviews Urology 12, n.º 7 (9 de junho de 2015): 361. http://dx.doi.org/10.1038/nrurol.2015.135.
Texto completo da fonteLohiya, Vipin, Jeanny B. Aragon-Ching e Guru Sonpavde. "Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer". Clinical Medicine Insights: Oncology 10s1 (janeiro de 2016): CMO.S34535. http://dx.doi.org/10.4137/cmo.s34535.
Texto completo da fonteMu, Chao-Feng, Fude Cui, Yong-Mei Yin, Hyun-Jong Cho e Dae-Duk Kim. "Docetaxel-Loaded Chitosan-Cholesterol Conjugate-Based Self-Assembled Nanoparticles for Overcoming Multidrug Resistance in Cancer Cells". Pharmaceutics 12, n.º 9 (19 de agosto de 2020): 783. http://dx.doi.org/10.3390/pharmaceutics12090783.
Texto completo da fonteQian, Jiang, Sheliang Shen, Wei Chen e Nianping Chen. "Propofol Reversed Hypoxia-Induced Docetaxel Resistance in Prostate Cancer Cells by Preventing Epithelial–Mesenchymal Transition by Inhibiting Hypoxia-Inducible Factor 1α". BioMed Research International 2018 (2018): 1–9. http://dx.doi.org/10.1155/2018/4174232.
Texto completo da fonteAndo, Takayuki, Ayumu Hosokawa, Kohei Ogawa, Shinya Kajiura, Yuko Itaya, Akira Ueda, Yuji Tsukioka, Takashi Kobayashi, Naoki Horikawa e Toshiro Sugiyama. "Efficacy of weekly paclitaxel in patients with advanced gastric cancer with prior docetaxel-containing chemotherapy." Journal of Clinical Oncology 30, n.º 4_suppl (1 de fevereiro de 2012): 127. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.127.
Texto completo da fonteBowers, Laura, Aneesha Kulkarni e Stephen Hursting. "Obesity-Associated Leptin Signaling Promotes Chemotherapy Resistance in Basal-Like Breast Cancer: The Role of Tumor-Associated Macrophages". Current Developments in Nutrition 4, Supplement_2 (29 de maio de 2020): 311. http://dx.doi.org/10.1093/cdn/nzaa044_010.
Texto completo da fonteMiyazawa, Yoshiyuki, Nobuaki Shimizu, Yutaka Takezawa, Toshiyuki Nakamura, Takeshi Miyao, Hiroshi Nakayama, Sota Kurihara et al. "Exploratory study of prognostic factors in mCRPC patients who administered enzalutamide focusing on early PSA decline and PSA kinetics at PSA progression: Results of retrospective multicenter study." Journal of Clinical Oncology 37, n.º 7_suppl (1 de março de 2019): 292. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.292.
Texto completo da fonteKomura, Kazumasa, Seong Ho Jeong, Kunihiko Hinohara, Fangfang Qu, Xiaodong Wang, Masayuki Hiraki, Haruhito Azuma, Gwo-Shu Mary Lee, Philip W. Kantoff e Christopher J. Sweeney. "Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression". Proceedings of the National Academy of Sciences 113, n.º 22 (16 de maio de 2016): 6259–64. http://dx.doi.org/10.1073/pnas.1600420113.
Texto completo da fonteHalder, Sushanta, Sakthivel Muniyan, Ramakanth Chirravuri-Venkata, Rama Krishna Nimmakayala, Palanisamy Nallasamy, Hareesh B. Nair, Moorthy P. Ponnusamy, Surinder K. Batra e Parthasarathy Seshacharyulu. "Abstract 1756: Targeting LIFR/c-Myc Axis to Overcome Docetaxel Resistance in Prostate Cancer". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 1756. http://dx.doi.org/10.1158/1538-7445.am2023-1756.
Texto completo da fonteGlynn, Sharon A., Aidan Toner, Joe Lewis, Frank Sullivan, Laura Breen, Martin Clynes e Francis J. Giles. "Prostate cancer inhibitory activity of a novel dual inhibitor, EL102, in combination with docetaxel, and its effects on MDR1-mediated drug resistance in vitro." Journal of Clinical Oncology 30, n.º 15_suppl (20 de maio de 2012): e15126-e15126. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e15126.
Texto completo da fonteDing, Adeline B., Erika Heninger, Shannon R. Reese, Cristina Sanchez-de-Diego, Ravi C. Yada, Nan Sethakorn, Sheena C. Kerr et al. "Abstract 635: Osteoclasts mediate chemotherapy resistance in a fully humanized microphysiologic system of prostate cancer bone metastases". Cancer Research 84, n.º 6_Supplement (22 de março de 2024): 635. http://dx.doi.org/10.1158/1538-7445.am2024-635.
Texto completo da fonteThangaretnam, Krishnapriya, Islam MD Obaidul, Heng Lu, Dunfa Peng, Nadeem Sidiq Bhat, Mohammed Soutto e Zheng Chen. "Abstract 375: Smoking induces Wee1 expression through miRNA deregulation, promoting docetaxel resistance in esophageal adenocarcinoma". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 375. http://dx.doi.org/10.1158/1538-7445.am2023-375.
Texto completo da fonteDeshmukh, Chetan Dilip, Ganesh Divekar, Minish Mahendra Jain, Shailesh Arjun Bondarde e Niraj Bhatt. "Pharmacologic differences in taxanes leading to difference in clinical activity and toxicity." Journal of Clinical Oncology 31, n.º 15_suppl (20 de maio de 2013): e13567-e13567. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e13567.
Texto completo da fonteLi, Jia, Jing Ke, Cheng-lin Qin e Xun Zhu. "LINC00680 modulates docetaxel resistance in breast cancer via the miR-320b/CDKL5 axis". International Journal of Immunopathology and Pharmacology 36 (janeiro de 2022): 039463202211056. http://dx.doi.org/10.1177/03946320221105608.
Texto completo da fonteThomson, Alastair, Adam Pollard e Frances May Mark. "Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC)." Journal of Clinical Oncology 37, n.º 7_suppl (1 de março de 2019): 298. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.298.
Texto completo da fonteMukherji, Deborah, Carmel Jo Pezaro, Diletta Bianchini, Andrea Zivi e Johann Sebastian De Bono. "Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel." Journal of Clinical Oncology 30, n.º 5_suppl (10 de fevereiro de 2012): 17. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.17.
Texto completo da fonteNing, Yang-min, William D. Figg e William L. Dahut. "Reversal of Docetaxel Resistance With Bevacizumab and Thalidomide". Clinical Genitourinary Cancer 7, n.º 2 (agosto de 2009): E37—E38. http://dx.doi.org/10.3816/cgc.2009.n.020.
Texto completo da fonteHonma, Kimi, Kyoko Iwao-Koizumi, Fumitaka Takeshita, Yusuke Yamamoto, Teruhiko Yoshida, Kazuto Nishio, Shunji Nagahara, Kikuya Kato e Takahiro Ochiya. "RPN2 gene confers docetaxel resistance in breast cancer". Nature Medicine 14, n.º 9 (17 de agosto de 2008): 939–48. http://dx.doi.org/10.1038/nm.1858.
Texto completo da fonteGanju, Aditya, Murali M. Yallapu, Sheema Khan, Stephen W. Behrman, Subhash C. Chauhan e Meena Jaggi. "Nanoways to overcome docetaxel resistance in prostate cancer". Drug Resistance Updates 17, n.º 1-2 (abril de 2014): 13–23. http://dx.doi.org/10.1016/j.drup.2014.04.001.
Texto completo da fonteScherbakov, Alexander M., Anna A. Basharina, Danila V. Sorokin, Ekaterina I. Mikhaevich, Iman E. Mizaeva, Alexandra L. Mikhaylova, Tatiana A. Bogush e Mikhail A. Krasil’nikov. "Targeting hormone-resistant breast cancer cells with docetaxel: a look inside the resistance". Cancer Drug Resistance 6, n.º 1 (2023): 103–15. http://dx.doi.org/10.20517/cdr.2022.96.
Texto completo da fontevan Soest, Robert J., Martin E. van Royen, Ellen S. de Morrée, Erik A. C. Wiemer, Ron H. J. Mathijssen, Ronald De Wit e Wytske M. van Weerden. "Effects on androgen receptor nuclear import by docetaxel, cabazitaxel, abiraterone, and enzalutamide: Potential mechanism for cross-resistance in castration-resistant prostate cancer (CRPC)." Journal of Clinical Oncology 31, n.º 15_suppl (20 de maio de 2013): 5064. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5064.
Texto completo da fonteHaldar, Subhash, Rajeev Mishra, Sandrine Billet, Manish Thiruvalluvan, Veronica R. Placencio-Hickok, Anisha Madhav, Frank Duong et al. "Cancer epithelia-derived mitochondrial DNA is a targetable initiator of a paracrine signaling loop that confers taxane resistance". Proceedings of the National Academy of Sciences 117, n.º 15 (1 de abril de 2020): 8515–23. http://dx.doi.org/10.1073/pnas.1910952117.
Texto completo da fontePudova, Elena, Anastasiya Kobelyatskaya, Irina Katunina, Anastasiya Snezhkina, Kirill Nyushko, Maria Fedorova, Vladislav Pavlov et al. "Docetaxel Resistance in Castration-Resistant Prostate Cancer: Transcriptomic Determinants and the Effect of Inhibiting Wnt/β-Catenin Signaling by XAV939". International Journal of Molecular Sciences 23, n.º 21 (25 de outubro de 2022): 12837. http://dx.doi.org/10.3390/ijms232112837.
Texto completo da fontePouptsis, Athanasios, Styliani Germanou, Nick Waldron, Thomas Young, Madeha Khan, Simon Hughes, Debra Hannah Josephs, Sarah Maria Rudman, Deborah Enting e Simon Chowdhury. "Primary resistance in docetaxel and androgen deprivation therapy in metastatic castrate sensitive prostate cancer patients." Journal of Clinical Oncology 36, n.º 6_suppl (20 de fevereiro de 2018): 342. http://dx.doi.org/10.1200/jco.2018.36.6_suppl.342.
Texto completo da fonteRushworth, Linda K., Victoria Harle, Peter Repiscak, William Clark, Robin Shaw, Holly Hall, Martin Bushell, Hing Y. Leung e Rachana Patel. "In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer". Life Science Alliance 3, n.º 12 (8 de outubro de 2020): e202000770. http://dx.doi.org/10.26508/lsa.202000770.
Texto completo da fonteNoaman, Ali Sedeeq, e Ercan Caca. "Role of Gene Expression Profiling in Colorectal Cancer by Using Docetaxel and Lapatinib." INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE 15, n.º 03 (25 de setembro de 2024): 1607–12. http://dx.doi.org/10.25258/ijpqa.15.3.77.
Texto completo da fonteAssoun, Sandra, Luca Campedel, Morgan Roupret, Christophe Vaessen, Jerome Parra, Haide Angele Boostandoost, Eva Comperat et al. "Antitumor activity of abiraterone, enzalutamide, and docetaxel following treatment with diethystilbestrol in castration-resistant prostate cancer." Journal of Clinical Oncology 35, n.º 6_suppl (20 de fevereiro de 2017): e581-e581. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.e581.
Texto completo da fonte